Lacosamide come antiepilettico in add-on in pazienti affetti da epilessia secondaria a tumore cerebrale

Translated title of the contribution: Add-on lacosamide in brain tumor-related epilepsy. Preliminary report: Efficacy and tolerability

L. Dinapoli, M. Maschio, M. Mingoia, F. Sperati, A. Fabi, A. Pace, G. Petreri, P. Muti

Research output: Contribution to journalArticlepeer-review

Abstract

Aim of the study was to evaluate efficacy and tolerability of lacosamide (LCM) as add-on in brain tumor-related epilepsy (BTRE). We followed 14 patients suffering from BTRE who had already been treated with other AEDs and who had had not experienced adequate seizure control. Eleven patients underwent chemotherapy while being treated with LCM. Mean duration of follow up was 5.4 months (min

Translated title of the contributionAdd-on lacosamide in brain tumor-related epilepsy. Preliminary report: Efficacy and tolerability
Original languageItalian
Pages (from-to)195-197
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number144
Publication statusPublished - May 2012

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Add-on lacosamide in brain tumor-related epilepsy. Preliminary report: Efficacy and tolerability'. Together they form a unique fingerprint.

Cite this